IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock Has Consensus Target Price of $52.69 According to Analysts

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) have been given an average rating of “Moderate Buy” by the fifteen analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $52.69.

A number of analysts have recently weighed in on the company. Wedbush increased their price target on IDEAYA Biosciences from $58.00 to $60.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Guggenheim boosted their price objective on IDEAYA Biosciences from $54.00 to $57.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Truist Financial lowered their price objective on IDEAYA Biosciences from $63.00 to $59.00 and set a “buy” rating for the company in a research note on Wednesday, August 5th. Citizens Jmp restated a “market outperform” rating and set a $42.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, September 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Friday, July 17th.

IDEAYA Biosciences Stock Up 0.1%

Shares of IDEAYA Biosciences stock opened at $36.11 on Friday. The firm has a market cap of $3.17 billion, a P/E ratio of -18.61 and a beta of -0.04. IDEAYA Biosciences has a fifty-two week low of $26.05 and a fifty-two week high of $42.68. The business has a 50-day moving average price of $38.15 and a 200 day moving average price of $34.31.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Tuesday, August 4th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.16). The firm had revenue of $8.86 million for the quarter, compared to the consensus estimate of $8.02 million. IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%. The company’s quarterly revenue was up 8800.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.88) EPS. As a group, equities research analysts anticipate that IDEAYA Biosciences will post -4.38 earnings per share for the current year.

Insider Activity

In related news, CEO Yujiro Hata sold 26,338 shares of the stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $37.41, for a total value of $985,304.58. Following the sale, the chief executive officer owned 690,695 shares of the company’s stock, valued at $25,838,899.95. This trade represents a 3.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.70% of the company’s stock.

Institutional Trading of IDEAYA Biosciences

Institutional investors have recently made changes to their positions in the stock. Versant Capital Management Inc lifted its position in shares of IDEAYA Biosciences by 26.7% during the 2nd quarter. Versant Capital Management Inc now owns 2,825 shares of the company’s stock valued at $105,000 after acquiring an additional 596 shares during the last quarter. Hsbc Holdings PLC boosted its stake in shares of IDEAYA Biosciences by 3.9% during the 1st quarter. Hsbc Holdings PLC now owns 19,258 shares of the company’s stock worth $645,000 after acquiring an additional 725 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of IDEAYA Biosciences by 79.0% in the 3rd quarter. GAMMA Investing LLC now owns 2,315 shares of the company’s stock worth $89,000 after acquiring an additional 1,022 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of IDEAYA Biosciences in the 2nd quarter worth $43,000. Finally, Global Retirement Partners LLC acquired a new position in shares of IDEAYA Biosciences in the 4th quarter worth $61,000. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer. The company uses insights from tumor biology, cancer genetics and synthetic lethality to identify treatments designed to target specific molecular alterations in tumors.

Its development pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily in genetically defined cancers, including GNAQ- or GNA11-mutated uveal melanoma.